The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study
Open accessAbstract
BACKGROUND: Carbapenem-resistant Pseudomonas aeruginosa (CRPA) is a global threat, but the distribution and clinical significance of carbapenemases are unclear. The aim of this study was to define characteristics and outcomes of CRPA infections and the global frequency and clinical impact of carbapenemases harboured by CRPA. METHODS: We conducted an observational, prospective cohort study of CRPA isolated from bloodstream, respiratory, urine, or wound cultures of patients at 44 hospitals (10 countries) between Dec 1, 2018, and Nov 30, 2019. Clinical data were abstracted from health records and CRPA isolates were whole-genome sequenced. The primary outcome was 30-day mortality from the day the index culture was collected. We compared outcomes of patients with CRPA infections by infection type and across geographic regions and performed an inverse probability weighted analysis to assess the association between carbapenemase production and 30-day mortality. FINDINGS: We enrolled 972 patients (USA n=527, China n=171, south and central America n=127, Middle East n=91, Australia and Singapore n=56), of whom 581 (60%) had CRPA infections. 30-day mortality differed by infection type (bloodstream 21 [30%] of 69, respiratory 69 [19%] of 358, wound nine [14%] of 66, urine six [7%] of 88; p=0·0012) and geographical region (Middle East 15 [29%] of 52, south and central America 20 [27%] of 73, USA 60 [19%] of 308, Australia and Singapore three [11%] of 28, China seven [6%] of 120; p=0·0002). Prevalence of carbapenemase genes among CRPA isolates also varied by region (south and central America 88 [69%] of 127, Australia and Singapore 32 [57%] of 56, China 54 [32%] of 171, Middle East 27 [30%] of 91, USA ten [2%] of 527; p<0·0001). KPC-2 (n=103 [49%]) and VIM-2 (n=75 [36%]) were the most common carbapenemases in 211 carbapenemase-producing isolates. After excluding USA patients, because few US isolates had carbapenemases, patients with carbapenemase-producing CRPA infections had higher 30-day mortality than those with non-carbapenemase-producing CRPA infections in both unadjusted (26 [22%] of 120 vs 19 [12%] of 153; difference 9%, 95% CI 3-16) and adjusted (difference 7%, 95% CI 1-14) analyses. INTERPRETATION: The emergence of different carbapenemases among CRPA isolates in different geographical regions and the increased mortality associated with carbapenemase-producing CRPA infections highlight the therapeutic challenges posed by these organisms. FUNDING: National Institutes of Health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Basic local alignment search tool
Altschul, S. F., Gish, W., Miller, W., Myers, E. W., & Lipman, D. J. (1990) · Journal of Molecular Biology · doi:10.1006/jmbi.1990.9999 · Cited by 98,669
RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies
Stamatakis, A. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu033 · Cited by 32,291
Validation of a combined comorbidity index
Charlson, M., Szatrowski, T. P., Peterson, J., & Gold, J. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90129-5 · Cited by 6,587
High throughput ANI analysis of 90K prokaryotic genomes reveals clear species boundaries
Jain, C., Rodriguez-R, L. M., Phillippy, A. M., Konstantinidis, K. T., & Aluru, S. (2018) · Nature Communications · doi:10.1038/s41467-018-07641-9 · Cited by 5,748
BIGSdb: Scalable analysis of bacterial genome variation at the population level
Jolley, K. A., & Maiden, M. C. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-595 · Cited by 2,368
Feldgarden, M., Brover, V., Haft, D. H., Prasad, A. B., Slotta, D. J., Tolstoy, I., Tyson, G. H., Zhao, S., Hsu, C.-H., McDermott, P. F., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00483-19 · Cited by 1,459
Multiple Mechanisms of Antimicrobial Resistance in Pseudomonas aeruginosa: Our Worst Nightmare?
Livermore, D. M. (2002) · Clinical Infectious Diseases · doi:10.1086/338782 · Cited by 1,453
ARIBA: rapid antimicrobial resistance genotyping directly from sequencing reads
Hunt, M., Mather, A. E., Sánchez-Busó, L., Page, A. J., Parkhill, J., Keane, J. A., & Harris, S. R. (2017) · Microbial Genomics · doi:10.1099/mgen.0.000131 · Cited by 660
Wang, M., Earley, M., Chen, L., Hanson, B. M., Yu, Y., Liu, Z., Salcedo, S., Cober, E., Li, L., Kanj, S. S., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00399-6 · Cited by 363
Self-citationDesirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR)
Evans, S. R., Rubin, D., Follmann, D., Pennello, G., Huskins, W. C., Powers, J. H., Schoenfeld, D., Chuang-Stein, C., Cosgrove, S. E., Fowler, V. G., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ495 · Cited by 361
Self-citation
Cited by
Tamma, P. D., Heil, E. L., Justo, J. A., Mathers, A. J., Satlin, M. J., & Bonomo, R. A. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae403 · Cited by 1,191
Self-citationESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics
Miller, W. R., & Arias, C. A. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-024-01054-w · Cited by 862
Self-citationTamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad428 · Cited by 740
Self-citationAntimicrobial resistance: a concise update
Ho, C. S., Wong, C. T. H., Aung, T. T., Lakshminarayanan, R., Mehta, J. S., Rauz, S., McNally, A., Kintses, B., Peacock, S. J., de la Fuente-Nunez, C., et al. (2025) · The Lancet Microbe · doi:10.1016/j.lanmic.2024.07.010 · Cited by 634
Multidrug-resistant Gram-negative bacterial infections
Macesic, N., Uhlemann, A.-C., & Peleg, A. Y. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02081-6 · Cited by 315
Metadata
- Authors
- Reyes, J., Komarow, L., Chen, L., Ge, L., Hanson, B. M., Cober, E., Herc, E., Alenazi, T., Kaye, K. S., Garcia-Diaz, J., Li, L., Kanj, S. S., Liu, Z., Oñate, J. M., Salata, R. A., Marimuthu, K., Gao, H., Zong, Z., Valderrama-Beltrán, S. L., Yu, Y., Tambyah, P., Weston, G., Salcedo, S., Abbo, L. M., Xie, Q., Ordoñez, K., Wang, M., Stryjewski, M. E., Munita, J. M., Paterson, D. L., Evans, S., Hill, C., Baum, K., Bonomo, R. A., Kreiswirth, B. N., Villegas, M. V., Patel, R., Arias, C. A., Chambers, H. F., Fowler, V. G., Doi, Y., van Duin, D., Satlin, M. J., Reyes, J., Komarow, L., Chen, L., Ge, L., Hanson, B., Cober, E., Herc, E., Alenazi, T., Kaye, K., Garcia-Diaz, J., Li, L., Kanj, S., Liu, Z., Oñate, J., Salata, R., Marimuthu, K., Gao, H., Zong, Z., Valderrama-Beltrán, S., Yu, Y., Tambyah, P., Weston, G., Salcedo, S., Abbo, L., Xie, Q., Ordoñez, K., Wang, M., Stryjewski, M., Munita, J., Paterson, D., Evans, S., Hill, C., Baum, K., Bonomo, R., Kreiswirth, B., Virginia Villegas, M., Patel, R., Arias, C., Chambers, H., Fowler, V., Doi, Y., van Duin, D., & Satlin, M.
- Venue
- The Lancet Microbe
- Publisher
- Elsevier BV
- Published
- 2023-03
- Volume
- 4
- Issue
- 3
- Pages
- e159-e170
- ISSN
- 2666-5247 (ISSN-L)
- OpenAlex
- W4319661295
- Cited by
- 321
- References
- 25
- FWCI
- 22.41
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study. https://app.cochat.ai/papers/10.1016/s2666-5247(22)00329-9
- The paper
- Reyes, J., Komarow, L., Chen, L., Ge, L., Hanson, B. M., Cober, E., Herc, E., Alenazi, T., Kaye, K. S., Garcia-Diaz, J., Li, L., Kanj, S. S., Liu, Z., Oñate, J. M., Salata, R. A., Marimuthu, K., Gao, H., Zong, Z., Valderrama-Beltrán, S. L., . . . Satlin, M. (2023). Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study. The Lancet Microbe. https://doi.org/10.1016/s2666-5247(22)00329-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.